ADAP
Price
$0.23
Change
-$0.01 (-4.17%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
63.53M
36 days until earnings call
MNKD
Price
$3.59
Change
-$0.15 (-4.01%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
1.14B
36 days until earnings call
Interact to see
Advertisement

ADAP vs MNKD

Header iconADAP vs MNKD Comparison
Open Charts ADAP vs MNKDBanner chart's image
Adaptimmune Therapeutics
Price$0.23
Change-$0.01 (-4.17%)
Volume$438
Capitalization63.53M
MannKind
Price$3.59
Change-$0.15 (-4.01%)
Volume$109.68K
Capitalization1.14B
ADAP vs MNKD Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. MNKD commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and MNKD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (ADAP: $0.24 vs. MNKD: $3.74)
Brand notoriety: ADAP and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 51% vs. MNKD: 142%
Market capitalization -- ADAP: $63.53M vs. MNKD: $1.14B
ADAP [@Biotechnology] is valued at $63.53M. MNKD’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while MNKD’s TA Score has 6 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 6 bearish.
  • MNKD’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than ADAP.

Price Growth

ADAP (@Biotechnology) experienced а -1.11% price change this week, while MNKD (@Biotechnology) price change was -1.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

MNKD is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.14B) has a higher market cap than ADAP($63.5M). MNKD YTD gains are higher at: -41.835 vs. ADAP (-55.504). MNKD has higher annual earnings (EBITDA): 82.6M vs. ADAP (-50.18M). MNKD has more cash in the bank: 182M vs. ADAP (59.6M). MNKD (47.2M) and ADAP (48.7M) have identical debt. MNKD has higher revenues than ADAP: MNKD (298M) vs ADAP (180M).
ADAPMNKDADAP / MNKD
Capitalization63.5M1.14B6%
EBITDA-50.18M82.6M-61%
Gain YTD-55.504-41.835133%
P/E RatioN/A37.40-
Revenue180M298M60%
Total Cash59.6M182M33%
Total Debt48.7M47.2M103%
FUNDAMENTALS RATINGS
ADAP vs MNKD: Fundamental Ratings
ADAP
MNKD
OUTLOOK RATING
1..100
5252
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
10055
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6588
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (48) in the Biotechnology industry is in the same range as ADAP (53). This means that MNKD’s stock grew similarly to ADAP’s over the last 12 months.

MNKD's Profit vs Risk Rating (55) in the Biotechnology industry is somewhat better than the same rating for ADAP (100). This means that MNKD’s stock grew somewhat faster than ADAP’s over the last 12 months.

ADAP's SMR Rating (97) in the Biotechnology industry is in the same range as MNKD (100). This means that ADAP’s stock grew similarly to MNKD’s over the last 12 months.

ADAP's Price Growth Rating (65) in the Biotechnology industry is in the same range as MNKD (88). This means that ADAP’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ADAP (100). This means that MNKD’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPMNKD
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 15 days ago
77%
Bullish Trend 29 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OGMCX31.95N/A
N/A
Invesco Gold & Special Minerals C
GHTMX15.24N/A
N/A
Goldman Sachs International T/M Eq Instl
JACTX55.86N/A
N/A
Janus Henderson Forty T
JERTX12.01N/A
N/A
Janus Henderson Global Real Estate T
DLCIX22.63N/A
N/A
Dana Large Cap Equity Institutional

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-2.16%
AKBA - ADAP
41%
Loosely correlated
-0.27%
ORMP - ADAP
36%
Loosely correlated
+4.65%
CSLLY - ADAP
32%
Poorly correlated
+2.78%
AXON - ADAP
31%
Poorly correlated
+1.14%
NTLA - ADAP
30%
Poorly correlated
-1.88%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-0.53%
VCYT - MNKD
44%
Loosely correlated
-1.28%
LXRX - MNKD
42%
Loosely correlated
+15.20%
INSM - MNKD
40%
Loosely correlated
+1.16%
BLUE - MNKD
38%
Loosely correlated
N/A
UTHR - MNKD
38%
Loosely correlated
+1.15%
More